UNSPSC 51351626: Estradiol undecylate

This classification denotes an estrogen C29H44O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H3N3A8MFJC, chemically known as estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 17-undecanoate, but more generally known as estradiol undecylate, which bears US NIH Compound Identifier 19135. European Medicines Agency schedules Estradiol undecylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07244MIG.

Most nations, for tariff and trade purposes, schedule estradiol undecylate under HS 29372300 and SITC 54153. As of Q4 2014, ESTRADIOL UNDECYLATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4C3CCC(C4)O)C.

UNSPSC 51351626 Estradiol undecylate, a Commodity code, encompasses pharmaceutical active ingredients and finished-dose hormone products procured by state and local government health systems, Medicaid programs, and cooperative purchasing alliances. State and local buyers under this code source estradiol undecylate primarily through multistate pharmaceutical cooperative purchasing vehicles that aggregate demand across participating jurisdictions and establish framework agreements with authorized wholesalers and manufacturers. The products are typically used in state and local health department facilities, correctional health services, and public health clinics serving Medicaid-eligible and uninsured populations. Purchasing entities include state pharmacy agencies and cooperative alliances spanning multiple states, which negotiate pricing and supply terms on behalf of member counties, cities, and health authorities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including products with National Drug Codes matching estradiol undecylate formulations, to supply participating state and local facilities across Minnesota, Oregon, and other member jurisdictions. Awarded vendors must demonstrate cGMP certification and Drug Supply Chain Security Act compliance, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC), and accept pricing structures including flat price, net price formats (NF30, NF60, NF90), or WAC-minus models. The RFP weights price competitiveness at 75 percent of evaluation; the contract term is two years for new vendors with optional extensions through June 30, 2028, and all products must be marketplace-available by May 15, 2026 with effective agreement dates of July 1, 2026.